稳心颗粒联合阿替洛尔在气滞血瘀型冠心病CTA检查中的应用价值及对心率变异性的影响

摘要

Objective:To explore the effect of heart rate variability of Wenxin Granule Combined with atenolol on qi stagnation and blood stasis in patients with coronary heart disease, and to study the application value of drug combination in the CTA in diagnosis of coronary heart disease (CHD).Methods: The 122 cases of elderly coronary heart disease patients in our hospital were selected as the object of study. All patients were diagnosed as coronary heart disease, with 61 cases in each group. The control group patients accepted the atenolol as the core of the conventional clinical treatment measures, and the observation group took Wenxin Granule Combined with atenolol treatment, comparing heart rate variability in the time domain indexes before and after treatment and the incidence of ST segment deviation and arrhythmia between the two groups.Results: The SDNN, SDANN, SDNN-Index indexes in the observation group improved more significantly than those in the control group (t=2.614,t=3.547,t=2.119, t=1.574,t=1.227,t=0.982;P<0.05). And SVE, SV-RUN, VE, V-tach were obviously superior to the control group. The differences were statistically significant (x2=2.517,x2=2.956,x2=1.845,x2=1.523;P<0.05). RCA, lad, LCX image quality in the observation group were significantly better than those in the control group, and the differences were statistically significant (t=0.870,t=0.903,t=1.097;P<0.05).Conclusion: Wenxin Granule Combined with atenolol treatment can effectively improve the good qi stagnation and blood stasis in patients of coronary heart disease with arrhythmia and heart rate variability, and can effectively improve the imaging quality of coronary CTA, with clinical application and popularization value.%目的：探讨稳心颗粒联合阿替洛尔对气滞血瘀型冠心病患者心率变异性的影响，研究联合用药在冠心病螺旋CT冠状动脉血管造影(CTA)诊断中的应用价值。方法：选取122例中医辨证分型为气滞血瘀型的老年冠心病患者，采用数表法随机将其分为观察组和对照组，每组61例。观察组采用稳心颗粒联合阿替洛尔治疗；对照组采用以阿替洛尔为核心的常规临床治疗措施；比较两组治疗前后心率变异性各时域指标变化、ST段偏移以及心律失常发生率，探讨CTA对两组冠心病患者的诊断价值。结果：治疗后观察组患者窦性心搏间期标准差(SDNN)、窦性心搏间期平均标准差(SDANN)及标准差平均值(SDNN-Index)等指标较对照组改善更为显著，差异有统计学意义(t=2.614，t=3.547，t=2.119，t=1.574，t=1.227，t=0.982；P＜0.05)；治疗中及治疗后观察组室上性期前收缩(SVE)、短阵室上性异位搏动(SV-RUN)、室性期前收缩(VE)以及室性心动过速(V-tach)明显优于对照组，差异有统计学意义(x2=2.517，x2=2.956，x2=1.845，x2=1.523；P＜0.05)；并且观察组右冠脉(RCA)、左前降支(LAD)及左旋支(LCX)图像质量明显优于对照组，差异有统计学意义(t=0.870，t=0.903，t=1.097；P＜0.05)。结论：稳心颗粒联合阿替洛尔治疗方案可有效改善气滞血瘀型冠心病患者心律失常及心率变异性，可有效提高冠状动脉CTA成像质量。